This page needs to be proofread.

Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm==

Includes: medical surveillance following completed treatment
Use additional code to identify any applicable history of disease code (Z86.-. Z87.-)
Excludes1: aftercare following medical care (Z43-Z49, Z51)
surveillance of contraception (Z30.4-)
surveillance of prosthetic and other medical devices (Z44-Z46)

Z11 Encounter for screening for infectious and parasitic diseases

Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease.
Excludes1: encounter for diagnostic examination-code to sign or symptom
Z11.0 Encounter for screening for intestinal infectious diseases
Z11.1 Encounter for screening for respiratory tuberculosis
Z11.2 Encounter for screening for other bacterial diseases
Z11.3 Encounter for screening for infections with a predominantly sexual mode of transmission
Excludes2: encounter for screening for human immunodeficiency virus [HIV] (Z11.4)
encounter for screening for human papillomavirus (Z11.51)
Z11.4 Encounter for screening for human immunodeficiency virus [HIV]
Z11.5 Encounter for screening for other viral diseases
Excludes2: encounter for screening for viral intestinal disease (Z11.0)
Z11.51 Encounter for screening for human papillomavirus (HPV)
Z11.59 Encounter for screening for other viral diseases
Z11.6 Encounter for screening for other protozoal diseases and helminthiases
Excludes2: encounter for screening for protozoal intestinal disease (Z11.0)
Z11.8 Encounter for screening for other infectious and parasitic diseases
Encounter for screening for chlamydia
Encounter for screening for rickettsial
Encounter for screening for spirochetal
Encounter for screening for mycoses
Z11.9 Encounter for screening for infectious and parasitic diseases, unspecified

Z12 Encounter for screening for malignant neoplasms

Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease.
Use